GSK2251052: Suspended Phase IIb enrollment

Anacor said partner GlaxoSmithKline suspended enrollment in all trials of GSK2251052 following a "microbiological finding in a small number of patients" in a Phase IIb trial to treat complicated urinary tract infections (cUTI). Anacor is working with GSK to investigate the finding, which the biotech said could take several months. The Phase IIb trial is comparing 750 and 1,500 mg IV GSK2251052 every 12 hours vs. IV imipenem/cilastatin every 6 hours in about 200 patients. Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) markets Primaxin imipenem/cilastatin. GSK has exclusive, worldwide rights to develop and commercialize GSK2251052 from Anacor (see BioCentury, Aug. 9, 2010). ...